Author:
Nishimura Y,Komatsu S,Ichikawa D,Nagata H,Hirajima S,Takeshita H,Kawaguchi T,Arita T,Konishi H,Kashimoto K,Shiozaki A,Fujiwara H,Okamoto K,Tsuda H,Otsuji E
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Aitken A (2006) 14-3-3 proteins: a historic overview. Semin Cancer Biol 16 (3): 162–172
2. Arora S, Matta A, Shukla NK, Deo SV, Ralhan R (2005) Identification of differentially expressed genes in oral squamous cell carcinoma. Mol Carcinog 42 (2): 97–108
3. Bajpai U, Sharma R, Kausar T, Dattagupta S, Chattopadhayay TK, Ralhan R (2008) Clinical significance of 14-3-3 zeta in human esophageal cancer. Int J Biol Markers 23 (4): 231–237
4. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy vs chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376 (9742): 687–697
5. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54 (14): 3845–3852
Cited by
98 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献